Chemical Biology and Drug Design

AUGUST 9, 2023

A label-free proteomics technology was employed to investigate alterations in protein expression in LoVo cells treated with plumbagin. The LC-MS/MS proteomics assay revealed 78 proteins that were differentially expressed upon treatment with plumbagin.

Bioinformatics 100

Bioinformatics Protein Expression Treatment Research 100

Drug Discovery World

SEPTEMBER 25, 2024

Additionally, the dynamic nature of tumour biology means that these targets can change over time, or under treatment pressure, necessitating continuous research and adaptation.” Stefan Ries is Chief Scientific Officer at DISCO Pharmaceuticals, a German company specialising in finding targets for targeted therapies such as ADCs.

Therapies 162

Therapies Pharma Companies FDA Approval FDA 162

Drug Discovery World

NOVEMBER 8, 2023

Helmut Salih, MD, Professor for Translational Immunology, Medical Director, Clinical Collaboration Unit Translational Immunology, University Hospital Tuebingen and DKFZ Heidelberg, Germany; Co-Founder, TWYCE GmbH, on: ‘An optimised IgG-Based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers’. Claes Gustafsson, Ph.D,

Engineering 162

Engineering Protein Expression Therapies Science 162

Drug Discovery World

NOVEMBER 9, 2023

Sandra Ergueta-Carballo, PhD, Project Coordinator, University of Cambridge, on: ‘Advancing snake envenomation treatment: designing the next generation of antivenoms’. Jorge Dias, PhD, Principal Scientist, Alchemab Therapeutics, on: ‘A patient-first approach to discover first-in-class antibody therapeutics’.

Engineering 130

Engineering Therapies Protein Production Science 130